TY - JOUR
T1 - A Roadmap for Innovation to Advance Transplant Access and Outcomes
T2 - A Position Statement From the National Kidney Foundation
AU - Lentine, Krista L.
AU - Pastan, Stephen
AU - Mohan, Sumit
AU - Reese, Peter P.
AU - Leichtman, Alan
AU - Delmonico, Francis L.
AU - Danovitch, Gabriel M.
AU - Larsen, Christian P.
AU - Harshman, Lyndsay
AU - Wiseman, Alexander
AU - Kramer, Holly J.
AU - Vassalotti, Joseph
AU - Joseph, Jessica
AU - Longino, Kevin
AU - Cooper, Matthew
AU - Axelrod, David A.
N1 - Publisher Copyright:
© 2021 National Kidney Foundation, Inc.
PY - 2021/9
Y1 - 2021/9
N2 - Over the past 65 years, kidney transplantation has evolved into the optimal treatment for patients with kidney failure, dramatically reducing suffering through improved survival and quality of life. However, access to transplant is still limited by organ supply, opportunities for transplant are inequitably distributed, and lifelong transplant survival remains elusive. To address these persistent needs, the National Kidney Foundation convened an expert panel to define an agenda for future research. The key priorities identified by the panel center on the needs to develop and evaluate strategies to expand living donation, improve waitlist management and transplant readiness, maximize use of available deceased donor organs, and extend allograft longevity. Strategies targeting the critical goal of decreasing organ discard that warrant research investment include educating patients and clinicians about potential benefits of accepting nonstandard organs, use of novel organ assessment technologies and real-time decision support, and approaches to preserve and resuscitate allografts before implantation. The development of personalized strategies to reduce the burden of lifelong immunosuppression and support “one transplant for life” was also identified as a vital priority. The panel noted the specific goal of improving transplant access and graft survival for children with kidney failure. This ambitious agenda will focus research investment to promote greater equity and efficiency in access to transplantation, and help sustain long-term benefits of the gift of life for more patients in need.
AB - Over the past 65 years, kidney transplantation has evolved into the optimal treatment for patients with kidney failure, dramatically reducing suffering through improved survival and quality of life. However, access to transplant is still limited by organ supply, opportunities for transplant are inequitably distributed, and lifelong transplant survival remains elusive. To address these persistent needs, the National Kidney Foundation convened an expert panel to define an agenda for future research. The key priorities identified by the panel center on the needs to develop and evaluate strategies to expand living donation, improve waitlist management and transplant readiness, maximize use of available deceased donor organs, and extend allograft longevity. Strategies targeting the critical goal of decreasing organ discard that warrant research investment include educating patients and clinicians about potential benefits of accepting nonstandard organs, use of novel organ assessment technologies and real-time decision support, and approaches to preserve and resuscitate allografts before implantation. The development of personalized strategies to reduce the burden of lifelong immunosuppression and support “one transplant for life” was also identified as a vital priority. The panel noted the specific goal of improving transplant access and graft survival for children with kidney failure. This ambitious agenda will focus research investment to promote greater equity and efficiency in access to transplantation, and help sustain long-term benefits of the gift of life for more patients in need.
KW - Deceased donor organ transplantation
KW - disparities
KW - end-stage kidney disease (ESKD)
KW - graft survival
KW - immunosuppression
KW - kidney transplantation
KW - living donation
KW - organ donation
KW - patient survival
KW - research priorities
UR - http://www.scopus.com/inward/record.url?scp=85112514491&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2021.05.007
DO - 10.1053/j.ajkd.2021.05.007
M3 - Comment/debate
C2 - 34330526
AN - SCOPUS:85112514491
SN - 0272-6386
VL - 78
SP - 319
EP - 332
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -